Who
Philippe Amouyal
Director
Company insider
Files Form 4 as: Director, CAVA Group; Director, Lexicon Pharmaceuticals; Director, WW International; Director, Blue Buffalo Pet Products.
In numbers
- Trades disclosed
- 126
- Buys
- 3
- Sells
- 1
- Bought
- $890K
- Sold
- $567K
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 15 Dec 2006
- Last trade
- 22 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jun 2026filed 24 Jun 2026 | CAVA CAVA GroupRestaurants | SEC FORM 4 Code A | —1,881 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | CAVA CAVA GroupRestaurants | SEC FORM 4 Code A | —1,881 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,714 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —43,478 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,714 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —43,478 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | CAVA CAVA GroupRestaurants | SEC FORM 4 Code A | —1,767 at $0.00 | filing |
| 3 Jun 2025filed 3 Jun 2025 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —103,806 at $0.00 | filing |
| 3 Jun 2025filed 3 Jun 2025 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —89,312 at $0.00 | filing |
| 13 May 2025filed 13 May 2025 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —36,810 at $0.00 | filing |
| 13 May 2025filed 13 May 2025 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —36,810 at $0.00 | filing |
| 20 Jun 2024filed 24 Jun 2024 | CAVA CAVA GroupRestaurants | SEC FORM 4 Code A | —1,307 at $0.00 | filing |
| 13 May 2024filed 13 May 2024 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,906 at $0.00 | filing |
| 13 May 2024filed 13 May 2024 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,810 at $0.00 | filing |
| 28 Apr 2024filed 29 Apr 2024 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,032 at $0.00 | filing |
| 28 Apr 2024filed 29 Apr 2024 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —8,032 at $0.00 | filing |
News
Critical Survey: CAVA Group (NYSE:CAVA) versus Trip.com Group (NASDAQ:TCOM)CAVA · themarketsdaily.com · 14 Oct 2026Analyzing ATA (NASDAQ:AACG) & WW International (NASDAQ:WW)WW · dailypolitical.com · 13 Oct 2026Head-To-Head Comparison: Papa John's International (NASDAQ:PZZA) & CAVA Group (NYSE:CAVA)CAVA · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Philippe Amouyal; 3 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.